Biomedical Engineering Reference
In-Depth Information
15. Oberdörster G, Oberdörster E, Oberdörster J (2005) Nanotoxicology: an emerging discipline
evolving from studies of ultrafine particles. Environ Health Perspect 113(7):823-839
16. Newman SP, Chan H-K (2008)
In vitro/in vivo
comparisons in pulmonary drug delivery.
J Aerosol Med Pulm Drug Deliv 21(1):1-8
17. Patton JS, Fishburn S, Weers JG (2004) The lungs as a portal of entry for systemic drug delivery.
Proc Am Thorac Soc 1(4):338-344
18. Hinds WC (1999) Aerosol technology: properties, behavior, and measurement of airborne
particles, 2nd edn. John Wiley & Sons, NY
19. Islam N, Gladki E (2008) Dry powder inhalers (DPIs)—a review of device reliability and
innovation. Int J Pharm 360(1-2):1-11
20. Hickey AJ, Concessio NM, VanOort MM, Platz RM (1994) Factors influencing the dispersion
of dry powders as aerosols. J Pharm Technol 18:58-64
21. Hickey AJ, Crowder (2007) Next generation dry powder delivery systems. In: Hickey AJ (ed)
Inhalation aerosols, 2nd edn. Informa HealthCare USA, NY, pp 445-460
22. Ashurst I, Malton A (2002) Passive dry powder inhalation technology. In: Rathbone MJ,
Hadgraft J, Roberts MS (eds) Modified-release drug delivery technology. Informa HealthCare,
NY, pp 867-877
23. Staniforth JN (1996) Pre-formulation aspects of dry powder aerosol. In: Dalby RN, Byron PR,
Farr SJ (eds) Respiratory drug delivery. Interpharm, Buffalo Grove, IL, pp 65-73
24. Borgström L, Borgström L (1994) Deposition patterns with Turbuhaler®. J Aerosol Med
7S1:S49-S53
25. Duddu SP, Sisk SA, Walter YH, Tarara TE, Trimble KR, Clark AR, Eldon MA, Elton RC,
Pickford M, Hirst PH, Newman SP, Weers JG (2002) Improved lung delivery from a passive
dry powder inhaler using an engineered Pulmosphere® powder. Pharm Res 19(5):689-695
26. Olsson B (1995) Aerosol particle generation from dry powder inhalers: can they equal pressur-
ized metered dose inhalers? J Aerosol Med 8S3:S13-S19
27. United States Pharmacopeial Convention (2012) USP 35-NF 30 Chapter 601: aerosols, nasal
sprays, metered-dose inhalers and dry powder inhalers. United States Pharmacopeial
Convention, Rockville, MD
28. European Directorate for the Quality of Medicines and Healthcare (EDQM) (2012) Preparations
for inhalation: aerodynamic assessment of fine particles. Section 2.9.18 - European
Pharmacopoeia [Apparatus B in versions up to 4th Edn. 2002], Council of Europe, Strasbourg,
France
29. European Agency for the Evaluation of Medicinal Products (EMA) (1998) Note for Guidance
on dry powder inhalers, CPMP/QWP/158/96, London, UK
30. Hoe S, Traini D, Chan H-K, Young PM (2009) Measuring charge and mass distributions in dry
powder inhalers using the electrical next generation impactor (eNGI). Eur J Pharm Sci
38(2):88-94
31. Purewal TS (1998) Formulations of metered dose inhalers. In: Purewal TS, Grant DG (eds)
Metered dose inhaler technology. CRC, Boca Raton, FL, pp 9-68
32. Smyth HDC, Evans RM, Hickey AJ (2007) Aerosol generation from propellant-driven metered
dose inhalers. In: Hickey AJ (ed) Inhalation aerosols, 2nd edn. Informa HealthCare USA, NY,
pp 399-416
33. Taylor G, Tran CH, Warren S, Thomas I, Marchetti G (2008) The Kemp HFA MDI valve for
the delivery of novel budesonide/formoterol fumarate combination formulations. In: Dalby
RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (eds) Respiratory drug delivery-2008.
Davis HealthCare Int. Publishing, River Grove, IL, pp 983-986
34. Stein SW (2008) Aiming for a moving target: challenges with impactor measurements of MDI
aerosols. Int J Pharm 355(1-2):53-61
35. Lange CF, Finlay WH (2000) Overcoming the adverse effect of humidity in aerosol delivery
via pressurized metered dose inhalers during mechanical ventilation. Am J Respir Crit Care
Med 161(5):1614-1618
Search WWH ::
Custom Search